PT  - JOURNAL ARTICLE
AU  - Masego Mmatli
AU  - Nontombi Marylucy Mbelle
AU  - John Osei Sekyere
TI  - Global Epidemiology and Genetic Environment of <em>mcr</em> genes: A One Health Systematic Review of Current and Emerging Trends
AID  - 10.1101/2022.02.28.22271560
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.28.22271560
4099  - http://medrxiv.org/content/early/2022/03/01/2022.02.28.22271560.short
4100  - http://medrxiv.org/content/early/2022/03/01/2022.02.28.22271560.full
AB  - Background Mobile colistin resistance (mcr) genes modify Lipid A molecules of the lipopolysaccharide, changing the overall charge of the outer membrane.Methods A systematic review of all studies published between January 2015 to July 2021 was performed. Included articles described mcr genes in the context of their genetic environment, fitness cost, crystal structure, their enzymatic activity and the risk factors associated with the acquisition of mcr. Studies describing the epidemiology of mcr genes and novel therapeutics were included.Results and Discussion Ten mcr genes have been described to date within eleven Enterobacteriaceae species, with Escherichia coli, Klebsiella pneumoniae, and Salmonella species being the most predominant. They are present worldwide in 72 countries, with human specimens currently having the highest incidence. This is due to the wide dissemination of mcr in livestock animals, meat, manure, the environment, and wastewater samples, increasing the risk of transmission via foodborne, zoonotic, and vector-borne routes to humans. The stability and spread of mcr genes were mediated by mobile genetic elements such as the IncHI2 conjugative plasmid, which is associated with multiple mcr-variants and other antibiotic resistance genes. The cost of acquiring mcr is reduced by compensatory adaptation mechanisms. MCR proteins are well conserved via structurally. Hence, MCR-1 inhibitors and therapeutics should be applicable to all MCR proteins.Conclusion Mcr genes have spread from animals into the clinical setting, threatening public health. Combination therapies are a promising option for managing and treating colistin-resistant Enterobacteriaceae isolates whilst reducing the toxic effects of colistin.Importance/HighlightsMcr genes are associated with mobile genetic elements that are facilitating its global dissemination.Using colistin as a growth promoter increases the risk of acquiring mcr-positive Enterobacteriaceae in food-producing animals.There is a higher incidence of mcr genes in humans than animals.MCR proteins are phosphoethanolamine (PEtN) transferases that mediate the transfer of PEtN from its primary phosphatidylethanolamine to lipid A.Multiple compounds can synergistically restore colistin’s activity, reducing its dosage and toxicity.CRISPR-Cas9, endolysins-engineered enzymes, and antimicrobial peptides are promising therapies for colistin resistanceTweet: “Within bacteria, mobile colistin resistance genes have spread widely, with a high incidence in human samples. It’s critical to comprehend the genetic tools facilitating this spread and their mechanisms of action. These are detailed in this paper, as are new therapeutic strategies for managing these resistance genes.”Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the NHLS development grant given to John Osei SekyereAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used for this work are publicly available and also attached as supplementary filesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are attached as supplementary files